Clinical Trials on Refractory Myelodysplastic Syndrome

Total 36494 results

National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

Unspecified Childhood Solid Tumor, Protocol Specific | Childhood Myelodysplastic Syndromes | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With... and other conditions

United States
Nkarta Inc.

Active, not recruiting

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

MDS | AML, Adult | Relapsed/Refractory AML | Refractory Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Patients With Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia With Ringed...

United States
Brian Jonas
Pharmacyclics LLC.

Completed

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Refractory Anemia With Excess Blasts in Transformation

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia,...

United States
Central Hospital, Nancy, France
Inserm U954 - N-GERE (Nutrition, Genetics and Exposition to Environmental...

Unknown

High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE) (MYRAGE)

High-risk Myelodysplastic Syndromes With Excess Blasts

France
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia...

United States
Brian Jonas
National Cancer Institute (NCI); Celgene; Pharmacyclics LLC.

Completed

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome

United States
Nuwacell Biotechnologies Co., Ltd.
The First Affiliated Hospital of University of Science and Technology of...

Not yet recruiting

A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes

Relapsed / Refractory Myelodysplastic Syndromes
Thomas Jefferson University
AbbVie

Recruiting

Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome

United States
Ruijin Hospital

Recruiting

Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS

Myelodysplastic Syndromes | Myelodysplastic Syndrome With Excess Blasts-2 | Myelodysplastic Syndrome With Excess Blasts-1

China
Case Comprehensive Cancer Center

Completed

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Thrombocytopenia | Chronic Myelomonocytic Leukemia | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Ringed Sideroblasts

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome

Severe Aplastic Anemia (SAA) | Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Not yet recruiting

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Relapsed Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Terminated

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

Myelodysplastic Syndrome | MDS | Refractory Anemia With Excess Blasts | RAEB

United States, Spain, Canada, France, Australia, Switzerland, Israel, Japan, Belgium, India, Ireland, United Kingdom, Croatia, Czechia, Poland, Estonia, Germany, Italy, Austria, Hungary, Russian Federation, Sweden
Dana-Farber Cancer Institute
National Institutes of Health (NIH); Brigham and Women's Hospital

Completed

Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
Vanderbilt-Ingram Cancer Center
Astex Pharmaceuticals, Inc.; Forma Therapeutics, Inc.

Withdrawn

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Jazz Pharmaceuticals

Terminated

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 | Myeloid Neoplasm

United States
National Cancer Institute (NCI)
Children's Oncology Group

Completed

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Celgene

Recruiting

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome With Excess Blasts | IDH2 Gene Mutation | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 20-30 Percent of Bone Marrow Nucleated Cells

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Completed

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in Transformation

United States
NextCure, Inc.

Recruiting

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Chronic Myelomonocytic Leukemia | Relapsed or Refractory Myelodysplastic Syndrome

United States
Eric Stephen Winer, MD

Recruiting

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

United States
University of Ulm
Sunesis Pharmaceuticals

Completed

Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)

Germany
Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
Stichting Hemato-Oncologie voor Volwassenen Nederland
Astellas Pharma Global Development, Inc.; Deutsch-Österreichische Studiengruppe...

Active, not recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Netherlands, Belgium, Germany, Switzerland, Australia, Finland, Norway, Sweden, Austria, France, Ireland, Lithuania, Luxembourg, Spain
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Recruiting

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Myelodysplastic Syndromes | AML, Adult | ALL, Adult | CLL, Refractory | CML, Refractory

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome

United States
Apollo Therapeutics Ltd

Not yet recruiting

A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS

Myelodysplastic Syndrome With Excess Blasts | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Myelodysplastic Syndrome Acute Myeloid Leukemia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome

United States
IGF Oncology, LLC

Terminated

IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic | Anemia, Refractory, With Excess of Blasts

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis

Recruiting

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome

United States
Masonic Cancer Center, University of Minnesota

Recruiting

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

Myelodysplastic Syndromes | Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Childhood Acute Myeloid Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Myeloid Leukemia | Secondary Myelodysplastic Syndrome and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blasts More Than 10 Percent of Bone Marrow Nucleated Cells

United States
National Cancer Institute (NCI)

Active, not recruiting

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Myeloproliferative Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents

Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and...

Terminated

Study of Velcade and Thalidomide in Patients With Myelodysplasia

Myelodysplastic Syndrome

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia... and other conditions

United States
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Cytopenia | Refractory Anemia With Excess Blasts

United States, Australia, Spain, Italy, Germany, France, Sweden, Denmark
National Cancer Institute (NCI)

Active, not recruiting

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Refractory Anemia | Myelodysplastic Syndrome With Ring Sideroblasts

United States
Roswell Park Cancer Institute
Celldex Therapeutics

Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Refractory Anemia | Blasts 30 Percent or Less of Bone Marrow Nucleated Cells

United States
Children's Oncology Group

Not yet recruiting

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Juvenile Myelomonocytic Leukemia | Refractory Juvenile Myelomonocytic Leukemia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Mixed Phenotype Acute Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2 | Myelodysplastic Syndrome With Excess Blasts-1 | Myelodysplastic Syndrome/Acute Myeloid Leukemia

Canada, United States
Foghorn Therapeutics Inc.

Recruiting

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Relapsed Acute Myeloid Leukemia | Relapsed Myelodysplastic Syndromes | Refractory Myelodysplastic Syndromes | Advanced Hematologic Malignancy | Relapsed Chronic Myelomonocytic Leukemia

United States
Amgen

Completed

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Refractory Cytopenias

Clinical Trials on Refractory Myelodysplastic Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations